Andrew Koustenis
- Oncology top 5%
- Lung Cancer Research Studies 12
- Cancer Treatment and Pharmacology 3
- HER2/EGFR in Cancer Research 3
-
- Lung Cancer Treatments and Mutations 13
- Advanced Breast Cancer Therapies 9
- Lung Cancer Diagnosis and Treatment 8
- Genetics top 10%
- Cancer Research top 10%
- Ophthalmology top 5%
-
- Cancer Mechanisms and Therapy 3
-
- Head and Neck Cancer Studies 3
- Co-authors
- Sara M. TolaneyMaura N. DicklerVéronique DièrasJavier CortésDebra A. PattJosé BaselgaHans WildiersHope S. Rugo
- Journals
- Journal of Clinical Oncology (10 papers)Journal of the American College of Cardiology (1 paper)Cancer (1 paper)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Andrew Koustenis
30 papers receiving 1.0k citations
Hit Papers
Peers
Comparison fields: 5 of 58
- Oncology 686
- Pulmonary and Respiratory Medicine 758
- Genetics 151
- Cancer Research 204
- Ophthalmology 117
Countries citing papers authored by Andrew Koustenis
This map shows the geographic impact of Andrew Koustenis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Koustenis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Koustenis more than expected).
Fields of papers citing papers by Andrew Koustenis
This network shows the impact of papers produced by Andrew Koustenis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Koustenis. The network helps show where Andrew Koustenis may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andrew Koustenis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2023 | 1 | |
| 3 | 2022 | 16 | |
| 4 | 2018 | 9 | |
| 5 | 2018 | 2 | |
| 6 | 2017 | 3 | |
| 7 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancerbreakdown → | 2017 | 490 |
| 8 | 2017 | 1 | |
| 9 | 2017 | 6 | |
| 10 | 2017 | 1 | |
| 11 | 2016 | 134 | |
| 12 | 2016 | 4 | |
| 13 | 2016 | 52 | |
| 14 | 2015 | 44 | |
| 15 | 2014 | 120 | |
| 16 | 2013 | 12 | |
| 17 | 2013 | 27 | |
| 18 | 2012 | 26 | |
| 19 | 2012 | 28 | |
| 20 | 2010 | 5 |
About Andrew Koustenis
Andrew Koustenis is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine, having authored 31 papers that have together received 1.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (12 papers), Advanced Breast Cancer Therapies (9 papers), Lung Cancer Diagnosis and Treatment (8 papers), Cancer Mechanisms and Therapy (3 papers), Cancer Treatment and Pharmacology (3 papers), Head and Neck Cancer Studies (3 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Oncology (686 citations), Pulmonary and Respiratory Medicine (758 citations) and Genetics (151 citations). Andrew Koustenis has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Sara M. Tolaney, Maura N. Dickler, Véronique Dièras, Javier Cortés, Debra A. Patt, José Baselga, Hans Wildiers, Hope S. Rugo, Martin Frenzel and Clifford A. Hudis. Their work appears in journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.